Navigation Links
Bionovo Announces 2010 Highlights and Year-End Financial Results
Date:3/15/2011

and metabolic syndrome.
  • In July, Bionovo entered into a $15 million, at-the-market firm commitment financing agreement with Aspire Capital. Although the Company has not yet accessed this facility, it is still available under the original conditions. Further, Aspire Capital participated in the underwritten offering that closed in February, 2011.
  • The Company also announced additions to its network of advisors and consultants, including leading healthcare professionals with extensive experience in the development of therapeutic treatments:
  • Dr. Richard Weiner, PhD, Emeritus Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences, at the University of California, San Francisco.
  • Dr. Paul Pui-Hay But, PhD, Chief Scientist for the Food and Drug Authentication Laboratory Ltd., Hong Kong, China.

  • Full Year ResultsFor the year ended December 31, 2010 total revenues were $0.6 million compared with $0.3 million for the same period in 2009. Revenues in 2010 consisted of a Qualifying Therapeutic Discovery Project Credit of $0.5 million and $0.1 million in a National Institute of Health (NIH) grant drawdown.  Revenue in 2009 was comprised of approximately $55,000 in limited research services revenue combined with $0.2 million in NIH grant drawdown.

    For the year ended December 31, 2010 total operating expenses were $18.2 million compared with $16.6 million for the same period in 2009. The increase in 2010 operating expenses were primarily due to additional expenses to support our Menerba manufacturing process development.

    The net loss for the year ended December 31, 2010 was $17.7 million, or $0.80 per share, compared with a net loss of $16.4 million, or $0.98 per share, for the same period in 2009. The year-over-year increase in net loss was driven primarily by the expenses related to the Menerba manufacturing process development and 2010 director and employee performance bonuse
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    2. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    3. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
    4. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
    5. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
    6. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
    7. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
    8. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    9. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
    10. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
    11. Bionovo to Raise $3 Million Through Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
    (Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
    (Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
    Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
    ... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
    ... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
    Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
    (Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to ... cosmetic experts gathered to see if they could reach a consensus on the steps ... augmentation and facelifts. Overall, the group reached 90 percent consensus on a series of ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic ... potential patients alike on various plastic surgery procedures including, but not limited to, ... popular dermatology procedures like Botox and fillers. , Staying up to date ...
    (Date:7/31/2015)... ... 31, 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved ... percent year-over-year for the first six months ended June 30, 2015 compared with the ... beat last year’s record-revenue mark of $10.4 million. , “We know what our customers ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia ... Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach State ... , “Peach State Health Plan and our parent company, Centene Corporation, are dedicated ...
    Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
    ... ... , ... TN (PRWEB) February 3, 2010 -- King Pharmaceuticals, Inc. (NYSE:KG) today launched PainBalance, ... to healthcare professionals and others, helping them provide optimal, appropriate care for all ...
    ... ... in Proper Context , ... Francisco, CA (PRWEB) February 3, 2010 -- The Medpedia Project today announced Medpedia Clinical Trials, ... that are in process or about to begin. Other online sources already allow for searching ...
    ... ... ... College of Osteopathic Medicine (NYCOM) and School of Health Professions, in partnership with the Nassau ... campus Sports Complex. The free vaccine will be available for all members of the NYIT ...
    ... , NORCROSS, ... , U.S. Speedskating  Olympic team sports psychologist and sports psychology instructor for ... Colbert Report ,  yesterday, February 1st, 2010 . , Host ... aired several TV segments highlighting his many attempts to ,make the team,. ...
    ... found , TUESDAY, Feb. 2 (HealthDay News) -- Extended use ... able to kick the habit and reduces the risk that ... The study included 568 adults who smoked 10 or more ... smokers who used nicotine patches for the entire 24 weeks ...
    ... NASHVILLE, Tenn. , Feb. 2 Healthcare Realty ... stock cash dividend for the quarter ended December 31, 2009 ... share, is payable on March 4, 2010 to shareholders ... Realty Trust is a real estate investment trust that integrates owning, ...
    Cached Medicine News:Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 2Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 3Health News:King Launches Painbalance: Educational Initiative to Help Reduce the Burden of Pain 4Health News:Medpedia Launches New Clinical Trial Platform 2Health News:Medpedia Launches New Clinical Trial Platform 3Health News:Medpedia Launches New Clinical Trial Platform 4Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 2Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 3Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 4Health News:Ashworth College Instructor Dr. Nicole Detling Miller Appears on 'Colbert Report' 5Health News:Using Nicotine Patch Longer Boosts Efforts to Quit 2Health News:Healthcare Realty Trust Announces Fourth Quarter Dividend 2
    Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
    ... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
    Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
    The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
    Medicine Products: